COVID-19 lockdown beneficial effects on lung function in a cohort of cystic fibrosis patients

Servidio, Alessia Giuseppina; Capata, Giulia; Levantino, Laura; Riccio, Guglielmo; Contorno, Sarah; Barbi, Egidio; Maschio, Massimo

doi:10.1186/s13052-021-00970-4

Cited by 11 publications

(5 citation statements)

References 6 publications

(6 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other authors have also shown a stability/improvement in respiratory function of CF patients during/after lockdown in line with our data. In support of this result, a reduction in the number of hospitalisations and exacerbations has also been described in literature [20,21]. On the other hand, however, Greek Authors showed that in their CF patients there were no changes in BMI while in our population we described this increase only in the male population when compared with the female population [20].…”

Section: Discussionsupporting

confidence: 87%

COVID-19 Lockdown Impacts Among Patients with Cystic Fibrosis: An Italian Regional Reference Centre Experience

Boni¹,

Murciano²,

Luca³

et al. 2022

Front. Biosci. (Landmark Ed)

View full text Add to dashboard Cite

Background: Coronavirus pandemic has influenced our society with social distancing and management of chronic disease such as cystic fibrosis (CF). During the Italian lockdown from March to May 2020, CF patients reduced the number of outpatient visits, limited social interactions and spent more time at home. The aim of this study is to evaluate the impact of the lockdown on body mass index (BMI) and lung function tests on CF patients. Methods: We retrospectively reviewed clinical data about 111 CF patients followed in our Regional Cystic Fibrosis Reference Centre (Policlinico Umberto I, Rome) according to two periods: pre-lockdown (from October 2019-March 2020) and post-lockdown (from May 2020-October 2020). We collected data on nutritional (BMI and body weight) and lung function status; we chose the best values of the 'pre-lockdown' and 'post-lockdown' period for each patient. Patients were divided into 3 groups according to FEV1 value (Forced Expiratory Volume in the 1st second): group 1 (FEV1 <40%), group 2 (FEV1 40-70%), group 3 (FEV1 >70%). All patients received a telephone interview asking for the number of hours per week devoted to physical activity, number of pulmonary acute exacerbations and subjective evaluation of adherence to medical therapy, respiratory physiotherapy and diet, during the two periods. Results: Comparing weight, BMI and respiratory function between pre and post lockdown periods, we noticed an increase in weight during among overall patients. Male patients improved weight, BMI, FEF 25-75% (Forced Expiratory flow between 25% and 75% of vital capacity) and Tiffenau index more than female patients. The most severely compromised patients (group 1), showed a significant loss of both weight and BMI. Instead, patients with moderate respiratory function (group 2) showed a significant increase of both weight and BMI and a slightly reduced CVF (Forced Vital capacity). We found no differences among patients with good respiratory function (group 3). Comparing each clinical sub-groups, we noticed a significative improvement of weight (p = 0.018) and BMI (p = 0.030) among patients with moderate respiratory function compared to patients with compromised respiratory function. During lockdown, patients reported less physical activity, no variation in food amount and composition, more adherence to therapy (43%) and more consistent daily respiratory physiotherapy (47.6%). Conclusions: Lockdown period had benefit among CF patients in terms of weight in particular in male patient. The greatest benefit on nutritional state was observed in patients with moderate reduction of respiratory function. In addition, we noted a stabilization and sometimes a slight improvement of lung function, instead of a continuous and steady decline that is normally observed in CF patients. These beneficial effects are slight but significative, bearing in mind the general worsening that CF patients experience annually.

show abstract

Section: Discussionsupporting

confidence: 87%

COVID-19 Lockdown Impacts Among Patients with Cystic Fibrosis: An Italian Regional Reference Centre Experience

Boni¹,

Murciano²,

Luca³

et al. 2022

Front. Biosci. (Landmark Ed)

View full text Add to dashboard Cite

show abstract

“…Thee et al. [11] reported a decline in FEV 1 in a cohort of 42 paediatric patients over a 2-month lockdown period, whereas three studies demonstrated an improvement in FEV 1 [12] , [13] , [14] . These studies were not exclusive to a paediatric population, were of shorter duration (2–6 months), and in one, patients had access to elexacaftor/tezecaftor/ivacaftor therapy.…”

Section: Discussionmentioning

confidence: 99%

The impact of telehealth based care on paediatric cystic fibrosis outcomes

Rimbaldo¹,

Frayman²,

Shanthikumar³

2023

Journal of Cystic Fibrosis

View full text Add to dashboard Cite

“…The results of this high, rapid uptake of telehealth are less clear. Some studies have shown an improvement in lung function in pediatric and adult PwCF with a decrease in pulmonary exacerbations [64][65][66]. Others have shown a decrease in lung function in pediatric PwCF [67,68].…”

Section: Modernization Of Care Post-covid-19mentioning

confidence: 99%

A new era in cystic fibrosis care: always changing and adapting

Diener,

Huertero,

Stables-Carney

et al. 2023

Current Opinion in Pediatrics

View full text Add to dashboard Cite

Purpose of review This review focuses on sharing the current and changing cystic fibrosis (CF) care model. This includes changes in CF care as a chronic disease with availability of new revolutionary, highly effective therapies as well as incorporation of shared decision-making, coproduction of care, quality improvement, telemedicine, and remote patient monitoring. Recent findings Changes in the CF management, the CF patient population, and CF care team are described as well as how CF care has adapted to these changes. Summary CF is a chronic, multisystem disease requiring a large specialized multidisciplinary care team for effective treatment. With improvements in CF care and new treatments, people with CF are living longer and healthier lives. As new issues arise, the CF team needs to adapt. This was highlighted by the introduction of highly effective cystic fibrosis transmembrane conductance regulator modulator therapy, which targets the cellular defect in CF, the COVID-19 pandemic, which lead to the incorporation of telehealth and remote patient monitoring into the CF care model, and the partnering with people with CF and families through shared decision-making and coproduction.

show abstract

COVID-19 lockdown beneficial effects on lung function in a cohort of cystic fibrosis patients

Cited by 11 publications

References 6 publications

COVID-19 Lockdown Impacts Among Patients with Cystic Fibrosis: An Italian Regional Reference Centre Experience

COVID-19 Lockdown Impacts Among Patients with Cystic Fibrosis: An Italian Regional Reference Centre Experience

The impact of telehealth based care on paediatric cystic fibrosis outcomes

A new era in cystic fibrosis care: always changing and adapting

Contact Info

Product

Resources

About